- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 172
- States / cities
- Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 1,733
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity, Obesity, Morbid, Obesity; Endocrine, Bariatric Surgery Candidate
- Interventions
- Gastric mucosal devitalization
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 28 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Allergy
- Interventions
- Blood Sampling
- Other
- Lead sponsor
- Adiga Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Upland, California • Fairfax, Virginia
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
- Interventions
- NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
- Device · Radiation · Drug
- Lead sponsor
- Jonathan Schoenfeld, MD, MPH
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
- Interventions
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Malignant Neoplasm
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 11
- States / cities
- Brick, New Jersey • Holmdel, New Jersey • Jersey City, New Jersey + 7 more
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Medical Chart Review
- Procedure · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Chapel Hill, North Carolina • Seattle, Washington
- Conditions
- Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Opioid-use Disorder
- Interventions
- ALA-1000, buprenorphine sublingual film
- Drug
- Lead sponsor
- Alar Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cachexia, Pancreatic Cancer
- Interventions
- immunologic technique, laboratory biomarker analysis, biopsy
- Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor
- Interventions
- Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 19 Years
- Enrollment
- 932 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- cytology specimen collection procedure, laboratory biomarker analysis
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Human Immunodeficiency Virus, Obesity
- Interventions
- dual-energy X-ray absorptiometry (DEXA) scan, Carotid and branchial artery ultrasound, 2-hour oral glucose tolerace test, Blood collection
- Radiation · Other · Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Glioblastoma, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
- Interventions
- Blood sampling for Laboratory Developed Test (LDT) analysis
- Other
- Lead sponsor
- Progenity, Inc.
- Industry
- Eligibility
- 18 Years to 54 Years · Female only
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more
- Conditions
- Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
- Interventions
- Data and Specimen Collection
- Genetic
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor
- Interventions
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Sunitinib Malate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Duarte, California • Irvine, California • Orange, California + 4 more
- Conditions
- Malignant Glioma
- Interventions
- Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
- Conditions
- Eosinophilic Esophagitis, Gastroesophageal Reflux Disease
- Interventions
- Sample collection and Questionnaire
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Blood sampling
- Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 264
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 206 more